HIGHLIGHTS
Although the long-term effects of LCZ696 (sacubitril/valsartan) on cardiac dysfunction have been previously elucidated, the short-term effects on acute phase after acute MI is unknown.
Wild-type mice subjected to ligation of left anterior descending artery were randomly allocated to the vehicle, enalapril, or LCZ696 group 1 day after MI, resulting in the belief that LCZ696 could prevent cardiac rupture compared to the vehicle, whereas there was no significant difference in rate of cardiac rupture-free survival in the enalapril compared to the vehicle.
At 3 days after MI, the expression of interleukin-1b, interleukin-6, matrix MMP-9
mRNA and MMP-9 activity in the infarcted myocardium were significantly lower, plasma aldosterone levels were significantly lower, and cGMP levels were significantly higher, in the LCZ696 than the other groups.
In vitro assay using peritoneal macrophages found that the combination of valsartan plus LBQ657 (active form of sacubitril) reduced the LPS-induced gelatinolytic activity and MMP-9 mRNA expression of macrophages.
LCZ696 could suppress pro-inflammatory cytokines and extracellular matrix degradation in macrophages, and provides protection against post-MI cardiac rupture in mice.
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Effects of LCZ696 in Myocardial Infarction
Ishii et al. Figures 1D and 1E ). In the sham-operated mice, the same surgery was conducted without Ishii et al.
Effects of LCZ696 in Myocardial Infarction Figure 2B shows the LV rupture-free survival curves, indicating that the LCZ696 group had a significantly lower rate of death due to LV rupture compared with the vehicle (p < 0.01) and enalapril (p < 0.05) groups. Figure 2C shows the number of the mice that died of LV rupture, which occurred within 6 days after MI. The LV ¼ left ventricular; other abbreviation as in Figure 1 .
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(p ¼ 0.045) ( Figure 4J ). On the other hand, in the noninfarcted region, there were no significant differences in the expression levels of these mRNA. compared with the vehicle group) ( Figure 4L ). In the infarcted region, however, there were no significant differences in the expression levels of these mRNA.
GELATINOLYTIC ACTIVITY AND MACROPHAGE-DERIVED MMP LOCALIZATION IN INFARCTED REGION.
To determine gelatinolytic activity derived from the enhanced MMP-9 mRNA expression in the infarcted region, we performed in situ zymography and MMP-9 activity assay. Figure 5A shows representative in situ zymographic images of the infarcted region 3 days after MI.
Analysis of these images showed significantly lower gelatinolytic activity in LCZ696 than the vehicle (p < 0.001) and enalapril (p ¼ 0.001) groups (
Figure 5B). Activity assay showed that MMP-9 activity was significantly lower in LCZ696 compared with the vehicle (p ¼ 0.014) and enalapril (p ¼ 0.007) groups, whereas there were no differences in total MMP-9 among the three groups ( Figures 5C and 5D ). 
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Ishii et al. Figure 7C , the aldosterone/ cGMP ratio was significantly lower in the LCZ696 than Ishii et al.
Effects of LCZ696 in Myocardial Infarction The increase in the incidence of ischemic heart disease-related HF has become a global health and economic problem (21, 22) . Although HF is an important complication in the acute and chronic phases after acute MI, cardiac rupture is also a major lethal complication, even in the percutaneous coronary intervention era (23, 24) . To reduce cardiovascular events and all-cause mortality, early administration of angiotensin-converting enzyme inhibitors (ACEi), ARBs, and ß-blockers after MI is recommended by the current American and European guidelines (25, 26 ).
The present study indicated that treatment with the maximum dose of LCZ696, which did not lower baseline BP, improved survival during the acute phase of MI. The rates of overall survival and cardiac rupture-free survival were significantly improved in the LCZ696-treated group when compared to the untreated control animals, whereas there was no significant difference in the overall survival and cardiac rupture-free survival in the enalapril-treated VAL ¼ valsartan; other abbreviations as in Figure 4 .
group when compared to untreated control animals.
Although the %FS after MI was improved significantly in the LCZ696 animals, it was not statistically different from values in the enalapril-treated group.
Although ACEi has been established as a standard drug against chronic HF and cardiac remodeling after acute MI, enalapril did not improve the survival rate after MI compared to the vehicle group in the present study. However, because we chose the dose of 4 mg/kg of enalapril based on the absence of hemodynamic effects on BP, we cannot exclude that higher doses of enalapril would have had a beneficial effect on overall survival and cardiac rupture-free survival.
The discrepancy between the previous evidences and present findings might be due to the specific dose of enalapril which was a maximum dose that did not significantly lower baseline blood pressure, as measured by telemetry method. We aimed to investigate the nonhypotensive effects of LCZ696 because BP tends to be decreased on acute phase after severe MI in the clinical setting, and it is difficult for those patients to receive the dose that lowers blood pressure. The present study provides the novel finding MMP-9, prevents cardiac rupture (19, 20) . The main sources of MMP-9 during the acute phase of MI are thought to be neutrophils, macrophages, and the myocardium (13, 18, 20, 30) . The present study showed that LCZ696 significantly decreased MMP-9 mRNA expression and activity, which was associated with a significant reduction in the rate of cardiac rupture compared to the vehicle and enalapril groups.
Furthermore, in situ zymography showed that the extent of the gelatinolytic activity paralleled the extent of infiltration of macrophages ( Figures 3A   and 5A ), a finding similar to that reported in our previous studies (13, 31) . In addition, double immunofluorescence images identified MMP-positive macrophages in the infarcted myocardium 3 days after MI ( Figure 5E ). In vitro assay using peritoneal macrophages showed that the combination of valsartan plus LBQ657 reduced the LPS-induced gelatinolytic activity and MMP-9 mRNA expression of macrophages.
Thus, it is possible that LCZ696 may inhibit MMP-9 secretion by macrophages in infarcted lesions in the acute phase of MI.
Although the molecular mechanism by which LCZ696 inhibits MMP-9 in the infarcted myocardium is poorly understood, we believe that LCZ696 pro- Proposed model of the mechanism that LCZ696 (sacubitril/valsartan), which simultaneously regulate RAAS and NPS, can protect against cardiac rupture after MI through the suppression of pro-inflammatory cytokines and ECM degradation. ECM ¼ extracellular matrix;
NPS ¼ natriuretic peptide system; RAAS ¼ renin-angiotensin-aldosterone system; other abbreviations as in Figures 1 and 4 .
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CONCLUSIONS
We showed that LCZ696, despite non-antihypertensive 
